115 citations
,
March 2001 in “Baillière's best practice and research in clinical endocrinology and metabolism/Baillière's best practice & research. Clinical endocrinology & metabolism”
Key enzymes control androgen levels, affecting hormone activity and potential treatments.
Beta-sitosterol may inhibit 5-alpha reductase type2enzyme, potentially reducing DHT levels and promoting hair growth, similar to finasteride but possibly with fewer side effects. Its effectiveness and side effects compared to other treatments like saw palmetto and finasteride remain uncertain due to limited research.
The conversation discusses how different factors can stimulate type 1 and type2 isoforms of 5-alpha reductase, which are enzymes linked to hair loss. Specific treatments mentioned include oral Dutasteride and topical Finasteride.
GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.
Finasteride and dutasteride are discussed for hair loss, with concerns about their effects on neurosteroids and potential side effects like depression. Alternatives like topical estrogen and lifestyle changes are considered, with varying opinions on mental health and hair regrowth.
Male pattern baldness (MPB) may be an early warning sign for type2 diabetes due to its association with insulin resistance. Treatments discussed include testosterone therapy and finasteride, which affects hormone levels related to hair loss and insulin sensitivity.